Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
21 Leser
Artikel bewerten:
(0)

I-Flow Expands Pain Management Portfolio With New Stimulating Needles For ON-Q T-bloc Trays

CHICAGO, April 3, 2014 /PRNewswire/ -- American Society of Regional Anesthesia and Acute Pain Medicine Meeting (ASRA) (Booth #101) -I-Flow, LLC, a Kimberly-Clark Health Care Company and manufacturer of the ON-Q Pain Relief System (ON-Q), today announced the addition of premium echogenic stimulating Tuohy needles to its ON-Q T-bloc trays, providing additional guidance capabilities for peripheral nerve block placement.

ON-Q T-bloc trays and sets include needles, catheters and other pain management accessories, and are designed to aid in performing most continuous upper and lower extremity and truncal blocks. The new T-bloc trays will be on display during the American Society of Regional Anesthesia and Pain Medicine's (ASRA) 39th Annual Meeting, at the I-Flow booth (#101).

"The addition of echogenic stimulating Tuohy needles to our trays allows physicians to use ultrasound combined with nerve stimulation to achieve greater accuracy and better results," said Price St. Hilaire, Executive Director, Global Marketing, I-Flow. "This new offering represents I-Flow's commitment to providing healthcare professionals a total solution from one trusted partner."

To request a trial of the new ON-Q T-bloc trays with stimulating needles, contact I-Flow customer service at 1-800-448-3569.

Additional I-Flow activity at ASRA includes:

Clinical Symposium

-- Topic:

New & Emerging Nerve Block Procedures - Paravertebral, Fascia Iliaca and


Adductor Canal (Saphenous) Blocks (non-CME)



-- Presenter:

Theresa Bowling, M.D., Chairman of the Department of Anesthesiology at


Stamford Hospital (Stamford, CT)



-- Location:

Sheraton Chicago Hotel & Towers


II & III meeting rooms


301 East North Water Street


Chicago, IL 60611



-- Date & Time:

Friday, April 4, 7-8 a.m.

Admission is free and breakfast will be served. Participants may register online at: www.iflo.com/ASRAevent.

Whitepaper Preview: ON-Q vs. Exparel for Pain Management

Executives from I-Flow will be at booth #101 to discuss findings of a new Frost & Sullivan whitepaper, documenting clinician perspective that ON-Q delivers superior pain control over the full length of the post-operative period - and at a lower cost - compared to Exparel.

Findings from the research include:

  • According to anesthesiologists involved in the research, the actual duration of pain relief for Exparel was significantly shorter than marketed - 25 versus 72 hours. While Exparel provided better pain relief up to 12 hours, ON-Q provided superior pain relief from that point forward up to 96 hours, making it the ideal choice for longer-term pain management.
  • The anesthesiologists surveyed indicated that they experienced a greater reduction in narcotic use when using ON-Q, with 58 percent experiencing a major reduction, compared to just 35 percent for Exparel.
  • Hospitals are performing a greater percentage of orthopedic surgery cases using ON-Q (37 percent) and a lower percentage using Exparel (31 percent). Anesthesiologists reported the highest percentage of orthopedic cases (39 percent) using ON-Q.

About I-Flow
I-Flow, LLC, a Kimberly-Clark Health Care Company, is a global market leader in acute pain and ambulatory medication delivery, driving innovative clinical applications for surgical procedures and regional anesthesia that improve outcomes and advance patient care. Led by its surgical pain management line, the ON-Q Pain Relief System (ON-Q) provides reliable and simple non-narcotic, regional anesthesia therapies that are redefining post-surgical recovery by reducing many of the side effects customarily associated with narcotics. Clinical studies have shown that patients who receive ON-Q products generally get back to normal faster after surgery, resulting in shorter hospital stays, reduced costs and higher patient satisfaction. I-Flow also offers a comprehensive suite of sets and trays for performing peripheral nerve blocks, providing an unmet need and total product solution for I-Flow's clinician customers. Also as part of I-Flow's total solution, the Company offers in-depth training, education, consulting and clinical support along with medical device expertise. For more information, visit www.iflo.com.

SOURCE I-Flow, LLC

© 2014 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.